Dataset: Prognostic and Predictive Gene Signature for Adjuvant Chemotherapy in Resected Non-Small Cell Lung Cancer

Background: The JBR.10 trial demonstrated significant survival benefit from adjuvant cisplatin/vinorelbine (ACT) in stage IB-II NSCLC (HR...

Registered by ArrayExpress Uploader

View Dataset

Background: The JBR.10 trial demonstrated significant survival benefit from adjuvant cisplatin/vinorelbine (ACT) in stage IB-II NSCLC (HR 0.69, p=0.04), but stage IB patients did not derive significant benefit (HR: 0.94, p= 0.79). We hypothesized that expression profiling could identify stage-independent subgroups of patients who might benefit from adjuvant chemotherapy. Methods: Gene expression profiling was conducted on mRNA isolated from frozen JBR.10 tumor samples (either from patients under observation [OBS], or treated with ACT). The minimum gene set that selected for the greatest separation of good and poor prognosis patient subgroups in OBS patients was identified and this gene signature was used to classify patients into high and low risk for death after surgery, and predict ACT effect. The prognostic gene signature was additionally tested on ACT patients and publicly available microarray datasets. Results: A 15-gene signature separated OBS patients into equal high and low risk subgroups with significantly different prognoses (HR 15.02, 95% CI 5.12-44.04, p=0.0001). The signature was prognostic in both stage IB and II. It was also predictive of improved survival following ACT treatment in high-risk patients (HR 0.33, 95% CI 0.17-0.63, p=0.0005), but not in low risk patients (HR 3.67, 95% CI 1.22-11.06, p=0.0133; interaction p=0.0001). The prognostic effect of the signature was validated in two independent gene expression datasets of 169 stage I-II adenocarcinoma and 106 squamous cell carcinoma patients. Conclusions: This microarray-based 15-gene prognostic expression signature is stage and histology independent and may select early stage NSCLC patients who are most likely to benefit from adjuvant chemotherapy with cisplatin/vinorelbine. Keywords: Expression profiling by microarray; prognosis prediction 90 samples

Species:: human
Samples:: 90
Source:: E-GEOD-14814
PubMed:: 20823422
Updated:: Dec.12, 2014
Registered:: Jun.19, 2014

Factors: (via ArrayExpress)

Sample	CAUSE OF DEATH	POST SURGICAL TREATMENT	OS STATUS	AGE	SEX	HISTOLOGY TYPE	DSS TIME	DSS STATUS	OS TIME	STAGE
GSM371002	Other conditions	ACT	Dead	56.8	male	ADC	6.03	Alive	6.03
GSM37100	Lung cancer	OBS	Dead	57.4	female	ADC	2.04	dead	2.04	II
GSM371000	Alive	OBS	Alive	63.2	male	ADC	5.38	Alive	5.38
GSM370999	Alive	ACT	Alive	41	female	ADC	6.74	Alive	6.74
GSM370998	Alive	OBS	Alive	57	female	SQCC	5.68	Alive	5.68	II
GSM370997	Lung cancer	ACT	Dead	62	female	ADC	4.76	dead	4.76	II
GSM370996	Lung cancer	ACT	Dead	66.9	male	SQCC	6.66	dead	6.66	II
GSM370995	Lung cancer	ACT	Dead	75.3	male	SQCC	1.70	dead	1.70	II
GSM370994	Lung cancer	OBS	Dead	66.5	male	SQCC	1.14	dead	1.14
GSM370993	Lung cancer	OBS	Dead	55.8	male	SQCC	1.10	dead	1.10	II
GSM370992	Alive	ACT	Alive	58.4	female	ADC	4.89	Alive	4.89	II
GSM37099	Alive	ACT	Alive	57.4	male	SQCC	8.18	Alive	8.18
GSM370990	Alive	ACT	Alive	70.4	male	SQCC	7.77	Alive	7.77
GSM370989	Alive	OBS	Alive	65.3	male	SQCC	2.86	Alive	2.86	II
GSM370988	Other conditions	ACT	Dead	72.4	male	SQCC	5.67	Alive	5.67
GSM370987	Alive	ACT	Alive	66.3	female	ADC	3.51	Alive	3.51
GSM370986	Alive	ACT	Alive	69.7	female	ADC	3.95	Alive	3.95	II
GSM370985	Alive	OBS	Alive	67.4	male	ADC	4.46	Alive	4.46
GSM370984	Lung cancer	OBS	Dead	69.2	male	ADC	1.50	dead	1.50	II
GSM370983	Alive	ACT	Alive	62.1	male	SQCC	9.22	Alive	9.22	II
GSM370982	Lung cancer	OBS	Dead	59	male	SQCC	5.00	dead	5.00	II
GSM37098	Lung cancer	OBS	Dead	55.6	male	SQCC	2.43	dead	2.43	II
GSM370980	Alive	ACT	Alive	61.6	male	LCUC	9.01	Alive	9.01
GSM370979	Lung cancer	OBS	Dead	65.8	male	ADC	2.82	dead	2.82	II
GSM370978	Alive	ACT	Alive	69.4	female	SQCC	4.74	Alive	4.74
GSM370977	Lung cancer	OBS	Dead	60.4	female	LCUC	2.18	dead	2.18
GSM370976	Lung cancer	OBS	Dead	45.8	female	ADC	1.86	dead	1.86
GSM370975	Alive	ACT	Alive	51.2	male	SQCC	4.09	Alive	4.09
GSM370974	Other conditions	OBS	Dead	58.5	male	SQCC	1.96	Alive	1.96	II
GSM370973	Alive	ACT	Alive	45.4	male	SQCC	6.54	Alive	6.54	II
GSM370972	Lung cancer	ACT	Dead	50.5	male	LCUC	0.63	dead	0.63
GSM37097	Alive	ACT	Alive	59.1	male	SQCC	6.87	Alive	6.87	II
GSM370970	Alive	OBS	Alive	58.1	female	SQCC	6.86	Alive	6.86	II
GSM370969	Lung cancer	OBS	Dead	67.9	male	SQCC	0.78	dead	0.78
GSM370968	Alive	ACT	Alive	60.5	male	SQCC	7.04	Alive	7.04	II
GSM370967	Lung cancer	ACT	Dead	59.5	female	LCUC	0.43	dead	0.43	II
GSM370966	Alive	ACT	Alive	70.3	male	SQCC	5.31	Alive	5.31
GSM370965	Alive	OBS	Alive	64.3	male	SQCC	5.88	Alive	5.88
GSM370964	Other conditions	OBS	Dead	69	male	SQCC	3.17	Alive	3.17
GSM370963	Alive	OBS	Alive	54.8	male	SQCC	7.12	Alive	7.12
GSM370962	Lung cancer	OBS	Dead	63.5	male	ADC	2.28	dead	2.28	II
GSM37096	Alive	ACT	Alive	64.1	male	SQCC	6.24	Alive	6.24	II
GSM370960	Alive	OBS	Alive	74.4	male	SQCC	6.09	Alive	6.09	II
GSM370959	Alive	ACT	Alive	73.1	male	SQCC	5.12	Alive	5.12
GSM370958	Alive	ACT	Alive	56.5	female	ADC	5.03	Alive	5.03	II
GSM370957	Alive	OBS	Alive	62.8	male	SQCC	6.44	Alive	6.44
GSM370956	Alive	ACT	Alive	63.7	male	ADC	5.42	Alive	5.42
GSM370955	Lung cancer	OBS	Dead	66.5	male	LCUC	1.18	dead	1.18	II
GSM370954	Lung cancer	ACT	Dead	65.7	male	SQCC	1.88	dead	1.88
GSM370953	Alive	ACT	Alive	75.8	male	SQCC	7.88	Alive	7.88
GSM370952	Alive	OBS	Alive	69.6	male	SQCC	7.94	Alive	7.94
GSM37095	Alive	OBS	Alive	38.2	female	ADC	5.87	Alive	5.87
GSM370950	Lung cancer	OBS	Dead	42.7	male	LCUC	0.74	dead	0.74	II
GSM370949	Lung cancer	ACT	Dead	66.2	male	SQCC	1.64	dead	1.64	II
GSM370948	Alive	OBS	Alive	63.3	male	SQCC	6.76	Alive	6.76	II
GSM370947	Alive	ACT	Alive	48.8	male	SQCC	6.71	Alive	6.71	II
GSM370946	Lung cancer	OBS	Dead	56.4	male	SQCC	2.29	dead	2.29
GSM370945	Alive	ACT	Alive	61.6	male	SQCC	6.73	Alive	6.73
GSM370944	Alive	ACT	Alive	58.2	male	ADC	7.20	Alive	7.20	II
GSM370943	Alive	ACT	Alive	61.3	male	SQCC	7.43	Alive	7.43	II
GSM370942	Alive	ACT	Alive	72.9	male	SQCC	7.21	Alive	7.21
GSM37094	Lung cancer	ACT	Dead	62.7	male	ADC	3.74	dead	3.74	II
GSM370940	Alive	OBS	Alive	62.1	male	SQCC	7.94	Alive	7.94	II
GSM370939	Lung cancer	ACT	Dead	75.6	female	ADC	0.90	dead	0.90
GSM370938	Lung cancer	ACT	Dead	81.3	male	LCUC	1.20	dead	1.20
GSM370937	Lung cancer	ACT	Dead	65.4	male	SQCC	1.09	dead	1.09
GSM370936	Alive	ACT	Alive	53	female	SQCC	7.24	Alive	7.24
GSM370935	Alive	ACT	Alive	68.8	male	ADC	7.71	Alive	7.71	II
GSM370934	Alive	OBS	Alive	50.2	female	ADC	6.93	Alive	6.93
GSM370933	Other conditions	ACT	Dead	63.2	male	ADC	0.19	Alive	0.19	II
GSM370932	Alive	OBS	Alive	63.4	female	SQCC	8.02	Alive	8.02	II
GSM37093	Other conditions	ACT	Dead	59.4	male	ADC	6.09	Alive	6.09
GSM370930	Alive	ACT	Alive	48.2	female	SQCC	7.53	Alive	7.53	II
GSM370929	Alive	OBS	Alive	72.5	male	SQCC	3.00	Alive	3.00
GSM370928	Lung cancer	OBS	Dead	63.5	female	ADC	1.59	dead	1.59
GSM370927	Alive	ACT	Alive	66.6	male	SQCC	8.48	Alive	8.48
GSM370926	Other conditions	OBS	Dead	73	male	SQCC	6.17	Alive	6.17
GSM370925	Alive	ACT	Alive	73.3	male	SQCC	9.29	Alive	9.29	II
GSM370924	Alive	OBS	Alive	60.8	male	LCUC	8.55	Alive	8.55
GSM370923	Alive	ACT	Alive	48.3	male	LCUC	8.71	Alive	8.71
GSM370922	Other conditions	OBS	Dead	70.6	male	SQCC	1.66	Alive	1.66	II
GSM37092	Alive	ACT	Alive	65.5	male	ADC	8.60	Alive	8.60	II
GSM370920	Other conditions	ACT	Dead	67.2	female	ADC	0.03	Alive	0.03
GSM370919	Lung cancer	OBS	Dead	64.8	male	SQCC	0.69	dead	0.69	II
GSM370918	Lung cancer	OBS	Dead	69.2	male	SQCC	2.06	dead	2.06	II
GSM370917	Alive	ACT	Alive	65.7	female	ADC	8.23	Alive	8.23
GSM370916	Alive	ACT	Alive	57.1	male	LCUC	8.66	Alive	8.66	II
GSM370915	Lung cancer	ACT	Dead	64.1	male	SQCC	1.32	dead	1.32	II
GSM370914	Alive	OBS	Alive	53.4	male	SQCC	9.03	Alive	9.03
GSM370913	Alive	OBS	Alive	44.9	female	ADC	8.52	Alive	8.52	II